Diagnosis and Treatment of Premenstrual Dysphoric Disorder



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2002 Oct 1;66(7):1239-1249.

  Patient Information Handout

From 2 to 10 percent of women of reproductive age have severe distress and dysfunction caused by premenstrual dysphoric disorder, a severe form of premenstrual syndrome. Current research implicates mechanisms of serotonin as relevant to etiology and treatment. Patients with mild to moderate symptoms of premenstrual syndrome may benefit from nonpharmacologic interventions such as education about the disorder, lifestyle changes, and nutritional adjustments. However, patients with premenstrual dysphoric disorder and those who fail to respond to more conservative measures may also require pharmacologic management, typically beginning with a selective serotonin reuptake inhibitor. This drug class seems to reduce emotional, cognitive-behavioral, and physical symptoms, and improve psychosocial functioning. Serotoninergic antidepressants such as fluoxetine, citalopram, sertraline, and clomipramine are effective when used intermittently during the luteal phase of the menstrual cycle. Treatment strategies specific to the luteal phase may reduce cost, long-term side effects, and risk of discontinuation syndrome. Patients who do not respond to a serotoninergic antidepressant may be treated with another selective serotonin reuptake inhibitor. Low-dose alprazolam, administered intermittently during the luteal phase, may be considered as a second-line treatment. A therapeutic trial with a gonadotropin-releasing hormone agonist or danazol may be considered when other treatments are ineffective. However, the risk of serious side effects and the cost of these medications limit their use to short periods.

Millions of women of reproductive age have recurrent emotional, cognitive, and physical symptoms related to their menstrual cycles. These symptoms often recur discretely during the luteal phase of the menstrual cycle and may significantly interfere with social, occupational, and sexual functioning.

Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome (PMS), is diagnosed by the pattern of symptoms. According to a report by the Committee on Gynecologic Practice of the American College of Obstetricians and Gynecologists,1 up to 80 percent of women of reproductive age have physical changes with menstruation; 20 to 40 percent of them experience symptoms of PMS, while 2 to 10 percent report severe disruption of their daily activities. Menstruation-related physical discomfort, such as dysmenorrhea, may begin with menarche. Often this condition is superseded by PMS in late adolescence or the early 20s. These syndromes generally remain stable over time.

Diagnosis

In the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV), PMDD is classified as “depressive disorder not otherwise specified” and emphasizes emotional and cognitive-behavioral symptoms.2  At least five of the 11 specified symptoms must be present for a diagnosis of PMDD (Table 1).2 These symptoms should be limited to the luteal phase and should not represent amplification of preexisting depression, anxiety, or personality disorder. In addition, they must be confirmed prospectively by daily rating for at least two consecutive menstrual cycles. A symptom-free period during the follicular phase of the menstrual cycle is essential in differentiating PMDD from preexisting anxiety and mood disorders.

TABLE 1

Research Criteria for Premenstrual Dysphoric Disorder

A. In most menstrual cycles during the past year, five (or more) of the following symptoms were present for most of the time during the last week of the luteal phase, began to remit within a few days after the onset of the follicular phase, and were absent in the week postmenses, with at least one of the symptoms being either (1), (2), (3), or (4):

  1. Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts

  2. Marked anxiety, tension, feelings of being “keyed up” or “on edge”

  3. Marked affective lability (e.g., feeling suddenly sad or tearful or increased sensitivity to rejection)

  4. Persistent and marked anger or irritability or increased interpersonal conflicts

  5. Decreased interest in usual activities (e.g., work, school, friends, hobbies)

  6. Subjective sense of difficulty in concentrating

  7. Lethargy, easy fatigability, or marked lack of energy

  8. Marked change in appetite, overeating, or specific food cravings

  9. Hypersomnia or insomnia

  10. A subjective sense of being overwhelmed or out of control

  11. Other physical symptoms, such as breast tenderness or swelling, headaches, joint or muscle pain, a sensation of “bloating,” or weight gain

B. The disturbance markedly interferes with work or school or with usual social activities and relationships with others (e.g., avoidance of social activities, decreased productivity and efficiency at work or school).

C. The disturbance is not merely an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, dysthymic disorder, or a personality disorder (although it may be superimposed on any of these disorders).

D. Criteria A, B, and C must be confirmed by prospective daily ratings during at least two consecutive symptomatic cycles. (The diagnosis may be made provisionally prior to this confirmation.)


note:In menstruating females, the luteal phase corresponds to the period between ovulation and the onset of menses, and the follicular phase begins with menses. In nonmenstruating females (e.g., those who have had a hysterectomy), the timing of luteal and follicular phases may require measurement of circulating reproductive hormones.

Reprinted with permission from the American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:717–8. Copyright 1994.

TABLE 1   Research Criteria for Premenstrual Dysphoric Disorder

View Table

TABLE 1

Research Criteria for Premenstrual Dysphoric Disorder

A. In most menstrual cycles during the past year, five (or more) of the following symptoms were present for most of the time during the last week of the luteal phase, began to remit within a few days after the onset of the follicular phase, and were absent in the week postmenses, with at least one of the symptoms being either (1), (2), (3), or (4):

  1. Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts

  2. Marked anxiety, tension, feelings of being “keyed up” or “on edge”

  3. Marked affective lability (e.g., feeling suddenly sad or tearful or increased sensitivity to rejection)

  4. Persistent and marked anger or irritability or increased interpersonal conflicts

  5. Decreased interest in usual activities (e.g., work, school, friends, hobbies)

  6. Subjective sense of difficulty in concentrating

  7. Lethargy, easy fatigability, or marked lack of energy

  8. Marked change in appetite, overeating, or specific food cravings

  9. Hypersomnia or insomnia

  10. A subjective sense of being overwhelmed or out of control

  11. Other physical symptoms, such as breast tenderness or swelling, headaches, joint or muscle pain, a sensation of “bloating,” or weight gain

B. The disturbance markedly interferes with work or school or with usual social activities and relationships with others (e.g., avoidance of social activities, decreased productivity and efficiency at work or school).

C. The disturbance is not merely an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, dysthymic disorder, or a personality disorder (although it may be superimposed on any of these disorders).

D. Criteria A, B, and C must be confirmed by prospective daily ratings during at least two consecutive symptomatic cycles. (The diagnosis may be made provisionally prior to this confirmation.)


note:In menstruating females, the luteal phase corresponds to the period between ovulation and the onset of menses, and the follicular phase begins with menses. In nonmenstruating females (e.g., those who have had a hysterectomy), the timing of luteal and follicular phases may require measurement of circulating reproductive hormones.

Reprinted with permission from the American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:717–8. Copyright 1994.

Researchers have developed a reliable and valid self-reporting scale called the Daily Symptom Report (see patient information handout).3 The report consists of 17 common PMS symptoms, including 11 symptoms from the DSM-IV PMDD diagnostic criteria. Patients rate each symptom on a five-point scale, from zero (none) to 4 (severe). The scale provides guidance for scoring the severity of each symptom and may be used in the office setting by primary care physicians for diagnosis and assessment of PMDD.

Etiology

Currently, there is no consensus on the cause of PMDD. Biologic, psychologic, environmental and social factors all seem to play a part. Genetic factors are also pertinent: 70 percent of women whose mothers have been affected by PMS have PMS themselves, compared with 37 percent of women whose mothers have not been affected.4 There is a 93 percent concordance rate in monozygotic twins, compared with a rate of 44 percent in dizygotic twins.4 Genetic influences mediated phenotypically through neurotransmitters and neuroreceptors seem to play a significant role in the etiology.

Features of PMDD and depressive disorders—specifically atypical depression—overlap considerably. Symptoms of atypical depression (i.e., depressed mood, interpersonal rejection hypersensitivity, carbohydrate craving, and hypersomnia) are similar to those of PMDD. Thirty to 76 percent of women diagnosed with PMDD have a lifetime history of depression,5 compared with 15 percent of women of a similar age without PMDD. A family history of depression is common in women diagnosed with moderate to severe PMS.6 There is significant comorbidity between depression and PMDD. Despite this relationship, many patients with PMDD do not have depressive symptoms; therefore, PMDD should not be considered as simply a variant of depressive disorder.7

The effectiveness of selective serotonin reuptake inhibitors (SSRIs), administered only during the luteal phase of the menstrual cycle,814 highlights the difference between PMDD and depressive disorder. Acute treatment with SSRIs increases synaptic serotonin without the down-regulation of serotonin receptors needed for improvement in overt depression. This finding suggests that PMDD is possibly caused by altered sensitivity in the serotoninergic system in response to phasic fluctuations in female gonadal hormone. Other studies also favor the serotonin theory as a cause of PMDD. In particular, the efficacy of l-tryptophan,15 a precursor of serotonin, and of pyridoxine,16 which serves as a cofactor in the conversion of tryptophan into serotonin, also favors serotonin deficiency as a cause of PMDD. Carbohydrate craving, often a symptom of PMDD, is also mediated through serotonin deficiency.

Because PMDD only affects women of reproductive age, it is reasonable to assume that female gonadal hormones play a causative role, possibly mediated through alteration of serotoninergic activity in the brain. Estrogen and progesterone seem to modulate levels of monoamines, including serotonin. Eliminating the effect of ovarian gonadal hormones through the use of a gonadotropin-releasing hormone (GnRH) agonist relieves PMDD symptoms.17 Subsequent administration of estrogen and progesterone causes symptoms to return in women with PMS but not in those without PMS symptoms.18

Treatment

The goals of treatment in patients with PMDD are (1) symptom reduction and (2) improvement in social and occupational functioning, leading to an enhanced quality of life. Available treatment options are summarized in Tables 2 through 6.

LIFESTYLE CHANGES

Lifestyle changes may be valuable in patients with mildly severe symptoms and benefit their overall health. Aerobic exercise and dietary changes often reduce premenstrual symptoms.19,20 Decreasing caffeine intake can abate anxiety and irritability, and reducing sodium decreases edema and bloating. Many patients prefer to try lifestyle changes and/or nutritional supplements as a first step in the treatment of PMDD.

NUTRITIONAL SUPPLEMENTS

Many of the nutritional supplements described in Table 24,15,16,1922 have proven efficacy. A meta-analysis16 of nine randomized, placebo-controlled trials was conducted to ascertain the effectiveness of vitamin B6 in PMS management. The researchers concluded that vitamin B6, in dosages of up to 100 mg per day, is likely to benefit patients with premenstrual symptoms and premenstrual depression. In another study,21 research literature (from January 1967 to September 1999) was reviewed to evaluate the effectiveness of calcium carbonate in patients with PMS. The reviewers concluded that calcium supplementation in a dosage of 1,200 to 1,600 mg per day is a treatment option in women with PMS. Calcium supplementation (using Tums E-X) was found to reduce core premenstrual symptoms by 48 percent in 466 patients.22 Vitamin E, an antioxidant, seems to reduce the affective and physical symptoms of PMS.20 Tryptophan,15 a substrate for serotonin, may also benefit some patients.15

TABLE 2

Treatment Approaches to PMDD

Lifestyle changes

Regular, frequent, small balanced meals rich in complex carbohydrates and low in salt, fat, and caffeine19,20

Regular exercise19,20

Smoking cessation20

Alcohol restriction20

Regular sleep20

Nutritional supplements

Vitamin B6, up to 100 mg per day16

Vitamin E, up to 600 IU per day20

Calcium carbonate, 1,200 to 1,600 mg per day21,22

Magnesium, up to 500 mg per day20

Tryptophan, up to 6 g per day15

Nonpharmacologic treatments

Stress reduction and management20

Anger management4

Self-help support group20

Individual and couples therapy20

Cognitive-behavioral therapy23

Patient education20 about the cause, diagnosis, and treatment of PMS/PMDD

Light therapy20 with 10,000 Lx cool-white fluorescent light


PMDD = premenstrual dysphoric disorder; PMS = premenstrual syndrome.

Information from references 4, 15, 16, and 19 through 23.

TABLE 2   Treatment Approaches to PMDD

View Table

TABLE 2

Treatment Approaches to PMDD

Lifestyle changes

Regular, frequent, small balanced meals rich in complex carbohydrates and low in salt, fat, and caffeine19,20

Regular exercise19,20

Smoking cessation20

Alcohol restriction20

Regular sleep20

Nutritional supplements

Vitamin B6, up to 100 mg per day16

Vitamin E, up to 600 IU per day20

Calcium carbonate, 1,200 to 1,600 mg per day21,22

Magnesium, up to 500 mg per day20

Tryptophan, up to 6 g per day15

Nonpharmacologic treatments

Stress reduction and management20

Anger management4

Self-help support group20

Individual and couples therapy20

Cognitive-behavioral therapy23

Patient education20 about the cause, diagnosis, and treatment of PMS/PMDD

Light therapy20 with 10,000 Lx cool-white fluorescent light


PMDD = premenstrual dysphoric disorder; PMS = premenstrual syndrome.

Information from references 4, 15, 16, and 19 through 23.

NONPHARMACOLOGIC TREATMENTS

Almost invariably, psychosocial stressors should be addressed, either as a cause or a result of PMDD. Psychosocial stressors are known to alter brain neurochemistry and stress-related hormonal activity. Stress reduction, assertiveness training, and anger management can reduce symptoms and interpersonal conflicts. Women with negative views of themselves and the future caused or exacerbated by PMDD may benefit from cognitive-behavioral therapy.23 This kind of therapy can enhance self-esteem and interpersonal effectiveness, as well as reduce other symptoms.23 Educating patients and their families about the disorder can promote understanding of it and reduce conflict, stress, and symptoms.20

HERBAL THERAPIES

A recent study24  reviewed efficacy and safety data on herbal supplements marketed for women. The author concluded that two herbal products, evening primrose oil and chaste tree berry, have been effective in treating PMS (Table 3).2426 Other researchers25 have arrived at variable conclusions about the efficacy of evening primrose oil. It is thought to provide the gamma-linolenic acid required for synthesis of prostaglandin E1,24 one of the anti-inflammatory prostaglandins. Chaste tree berry may reduce prolactin levels,24,25 thereby reducing symptoms of breast engorgement. These herbal therapies have not been approved by the U.S. Food and Drug Administration (FDA) for use in PMDD, and their safety in pregnancy and lactation has not been established. Moreover, manufacturing standards for herbal products are not uniform.

TABLE 3

Herbal Therapies for PMDD

Herbal product Dosage Use recommendation Comments

Evening primrose oil24,25

500 mg per day to 1,000 mg three times per day

Days 17 through 28 of menstrual cycle

Most-studied of all herbs used in treatment of PMS

May provide a precursor for prostaglandin synthesis

Benefits breast tenderness

Safety data in pregnancy and lactation lacking

Not approved for this use by the FDA

Chaste tree berry2426

30 to 40 mg per day

Days 17 through 28 of menstrual cycle

May benefit breast symptoms

Inhibits prolactin production

Safety data lacking

Not approved for this use by the FDA


PMDD = premenstrual dysphoric disorder; PMS = premenstrual syndrome; FDA = U.S. Food and Drug Administration.

Information from references 24 through 26.

TABLE 3   Herbal Therapies for PMDD

View Table

TABLE 3

Herbal Therapies for PMDD

Herbal product Dosage Use recommendation Comments

Evening primrose oil24,25

500 mg per day to 1,000 mg three times per day

Days 17 through 28 of menstrual cycle

Most-studied of all herbs used in treatment of PMS

May provide a precursor for prostaglandin synthesis

Benefits breast tenderness

Safety data in pregnancy and lactation lacking

Not approved for this use by the FDA

Chaste tree berry2426

30 to 40 mg per day

Days 17 through 28 of menstrual cycle

May benefit breast symptoms

Inhibits prolactin production

Safety data lacking

Not approved for this use by the FDA


PMDD = premenstrual dysphoric disorder; PMS = premenstrual syndrome; FDA = U.S. Food and Drug Administration.

Information from references 24 through 26.

PHARMACOLOGIC INTERVENTIONS

Antidepressant and Anxiolytic Medications

The serotoninergic antidepressants are the first-line treatment of choice for severe PMDD (Table 4).814,2737 Fluoxetine, in a dosage of 20 mg per day, has been shown to be superior to placebo, whether used only during the luteal phase12 or throughout the full menstrual cycle.2729 In a review29 of seven controlled and four open-label clinical trials of fluoxetine, symptoms were significantly reduced in patients with PMDD.

TABLE 4

Pharmacologic Interventions: Antidepressant and Anxiolytic Medications

Agents Dosage Use recommendation Comments

SSRIs

Citalopram13,35

10 to 30 mgper day

Full cycle or luteal phase only

Benefits physical, cognitive, and emotional symptoms

Administration during luteal phase

Luteal-phase use is superior to continuous treatment

Not approved by FDA for this use

Fluoxetine12,27,29,35

20 mg per day

Full cycle or luteal phase only

Significant reduction of all symptoms

Decreased libido or delayed orgasm is most common side effect in long-term, continuous use

Approved by FDA for this use

Paroxetine30,35

10 to 30 mgper day

Full cycle

Benefits all symptoms

Transient GI and sexual side effects

Superior to maprotiline

Not approved by FDA for this use

Sertraline810,14,3133,35

50 to 150 mg per day

Full cycle or luteal phase only

Benefits all symptoms

Transient GI and sexual side effects

Approved by FDA for this use

Other serotoninergic antidepressants

Clomipramine11,34

25 to 75 mgper day

Full cycle or luteal phase only

Benefits all symptoms

Anticholinergic and sexual side effects

Not approved by FDA for this use

Anxiolytics

Alprazolam28,36,37

0.375 to 1.5 mg per day

Luteal phase

Interrupted use during the luteal phase can reduce the risk of drug dependence

Use only if SSRIs are ineffective

Not approved by FDA for this use


SSRIs = selective serotonin reuptake inhibitors; FDA = U.S. Food and Drug Administration; GI = gastrointestinal.

Information from references 8 through 14, and 27 through 37.

TABLE 4   Pharmacologic Interventions: Antidepressant and Anxiolytic Medications

View Table

TABLE 4

Pharmacologic Interventions: Antidepressant and Anxiolytic Medications

Agents Dosage Use recommendation Comments

SSRIs

Citalopram13,35

10 to 30 mgper day

Full cycle or luteal phase only

Benefits physical, cognitive, and emotional symptoms

Administration during luteal phase

Luteal-phase use is superior to continuous treatment

Not approved by FDA for this use

Fluoxetine12,27,29,35

20 mg per day

Full cycle or luteal phase only

Significant reduction of all symptoms

Decreased libido or delayed orgasm is most common side effect in long-term, continuous use

Approved by FDA for this use

Paroxetine30,35

10 to 30 mgper day

Full cycle

Benefits all symptoms

Transient GI and sexual side effects

Superior to maprotiline

Not approved by FDA for this use

Sertraline810,14,3133,35

50 to 150 mg per day

Full cycle or luteal phase only

Benefits all symptoms

Transient GI and sexual side effects

Approved by FDA for this use

Other serotoninergic antidepressants

Clomipramine11,34

25 to 75 mgper day

Full cycle or luteal phase only

Benefits all symptoms

Anticholinergic and sexual side effects

Not approved by FDA for this use

Anxiolytics

Alprazolam28,36,37

0.375 to 1.5 mg per day

Luteal phase

Interrupted use during the luteal phase can reduce the risk of drug dependence

Use only if SSRIs are ineffective

Not approved by FDA for this use


SSRIs = selective serotonin reuptake inhibitors; FDA = U.S. Food and Drug Administration; GI = gastrointestinal.

Information from references 8 through 14, and 27 through 37.

In one placebo-controlled study,30 paroxetine in a dosage of 10 to 30 mg per day improved mood and physical symptoms in patients with PMDD. Paroxetine was more effective than the noradrenaline reuptake inhibitor maprotiline.30 Sertraline in a dosage of 50 to 150 mg per day was superior to placebo whether used during the full menstrual cycle3133 or only during the luteal phase.810,14 Citalopram in a dosage of 10 to 30 mg per day was effective in one randomized, placebo-controlled trial.13 Interestingly, intermittent administration of citalopram during the luteal phase was found to be superior to continuous treatment. Clomipramine, a serotoninergic tricyclic antidepressant that affects the noradrenergic system, in a dosage of 25 to 75 mg per day used during the full cycle34 or intermittently during the luteal phase,11 significantly reduced the total symptom complex of PMDD.

In a recent meta-analysis35 of 15 randomized, placebo-controlled studies of the efficacy of SSRIs in PMDD, it was concluded that SSRIs are an effective and safe first-line therapy and that there is no significant difference in symptom reduction between continuous and intermittent dosing. Because fluoxetine, citalopram, clomipramine, and sertraline were effective if administered during the luteal phase only, these drugs may be used as first-line therapy and taken intermittently only during the luteal phase. Such an approach can reduce the risk of long-term side effects (e.g., weight gain), minimize discontinuation syndrome, and reduce the cost of care. SSRIs benefit the total symptom complex of PMDD, not only the mood-related symptoms. It should also be noted that fluoxetine and sertraline are the only two SSRIs with FDA approval for use in the treatment of PMDD.

Alprazolam, a high-potency benzodiazepine with mood-enhancing and anxiolytic effects, has been shown to be somewhat effective in patients with PMS.28,36,37 Because of the potential for drug dependence, alprazolam should be considered a second-line drug and used only if SSRIs fail to achieve an optimal response. Therapy should be limited to the luteal phase, and the agent should be given in low dosages—0.375 to 1.5 mg per day. The risk of drug dependence with alprazolam can be minimized by administering it only during the luteal phase of the menstrual cycle in patients without a history of substance abuse.

Hormonal Therapies

It has been shown that by inducing anovulation and amenorrhea, GnRH agonists, leuprolide, histrelin, and goserelin provide significant relief of symptoms in patients without comorbid depression.3840 However, these medications can induce menopausal symptoms such as hot flushes, vaginal dryness, fatigue, irritability, cardiac problems, and osteopenia. In women with a history of PMDD, treatment of induced menopause with estrogen39 or estrogen plus progestational agents18 can induce recurrent symptoms of PMDD. This finding supports the theory of an etiologic role for female gonadal hormones in PMDD.

Danazol (Danocrine), a weak androgen prescribed for patients with endometriosis, fibrocystic breast disease, and hereditary angioneurotic edema, is sometimes used to treat PMDD. The typical dosage is 100 mg twice a day. Such treatment can reduce symptoms but may result in anovulation and masculinization, either of which may limit regular use.41 Because of the potential for serious side effects and significant costs, GnRH agonists and danazol should be tried as a last resort. These medications must be initiated during menstruation to prevent teratogenicity if there is an unintended pregnancy.

Although oral contraceptive pills (OCPs) suppress ovulation, they are not reported to be consistently effective in the treatment of PMDD (perhaps because the studies had variable samples). OCPs may not suffice if mood symptoms are prominent and, in some patients, these drugs may worsen dysphoria (a known side effect of some birth control pills) in many women without PMDD.

Efficacy studies of progesterone have shown limited benefits. One study42 found progesterone to be superior to placebo; however, another study43  reported efficacy equal to or less than that of placebo. Currently, ovarian gonadal hormones are thought to be of limited usefulness in the treatment of PMDD, and none of the drugs has FDA approval for this indication (Table 5).18,20,3843

TABLE 5

Hormonal Therapies for PMDD

Drug Dosage Use recommendation Comments

Leuprolide depot38,40

3.75 mg IM per month

Up to six cycles

Pregnancy category X

Significant relief from symptoms but can induce menopausal syndrome

Leuprolide depot with ovarian hormone supplements18

3.75 mg IM per month with estrogen and progesterone

Can exceed six cycles

Less likely to induce menopause; PMDD symptoms may return, making this combination less effective

Goserelin with estrogen supplementation39

3.6 mg SC every 28 days with estrogen

Can exceed six cycles

Less likely to induce menopause; PMDD symptoms may return, making this combination less effective

Pregnancy category X

Use nonhormonal contraception during therapy and for 12 weeks after discontinuation of drug or until menses resume

Danazol41

100 mg twice a day

Up to six cycles

May cause masculinization from weak androgenic properties

Pregnancy category X

OCPs20

OCPs with varying amounts of estrogen and progesterone, once a day

Full cycle

Variable response; may not benefit patients with significant mood symptoms; in some patients, may make mood symptoms worse

Progesterone42,43

Vaginal suppositories, 200 to 400 mg per day

Not recommended for this use

Questionable efficacy


PMDD = premenstrual dysphoric disorder; IM = intramuscularly; SC = subcutaneously; OCPs = oral contraceptive pills.

Information from references 18, 20, and 38 through 43.

TABLE 5   Hormonal Therapies for PMDD

View Table

TABLE 5

Hormonal Therapies for PMDD

Drug Dosage Use recommendation Comments

Leuprolide depot38,40

3.75 mg IM per month

Up to six cycles

Pregnancy category X

Significant relief from symptoms but can induce menopausal syndrome

Leuprolide depot with ovarian hormone supplements18

3.75 mg IM per month with estrogen and progesterone

Can exceed six cycles

Less likely to induce menopause; PMDD symptoms may return, making this combination less effective

Goserelin with estrogen supplementation39

3.6 mg SC every 28 days with estrogen

Can exceed six cycles

Less likely to induce menopause; PMDD symptoms may return, making this combination less effective

Pregnancy category X

Use nonhormonal contraception during therapy and for 12 weeks after discontinuation of drug or until menses resume

Danazol41

100 mg twice a day

Up to six cycles

May cause masculinization from weak androgenic properties

Pregnancy category X

OCPs20

OCPs with varying amounts of estrogen and progesterone, once a day

Full cycle

Variable response; may not benefit patients with significant mood symptoms; in some patients, may make mood symptoms worse

Progesterone42,43

Vaginal suppositories, 200 to 400 mg per day

Not recommended for this use

Questionable efficacy


PMDD = premenstrual dysphoric disorder; IM = intramuscularly; SC = subcutaneously; OCPs = oral contraceptive pills.

Information from references 18, 20, and 38 through 43.

Miscellaneous Pharmacologic Interventions

In a double-blind, placebo-controlled, crossover study,44 spironolactone in a dosage of 100 mg per day was more effective than placebo in reducing irritability, depression, somatic symptoms, feelings of swelling, breast tenderness, and craving for sweets. Bromocriptine in a dosage of up to 2.5 mg three times per day may be beneficial in patients with cyclic mastalgia,4,20 although in one study45 it was not found to be effective. Ibuprofen, in a dosage of up to 1,000 mg per day, can reduce breast pain, headaches, back pain, and other pain symptoms,20  but seems to have limited effect on mood symptoms (Table 6).4,20,44,45

TABLE 6

Miscellaneous Pharmacologic Interventions for PMDD

Agents Dosage Use recommendation Comments

Diuretics

Spironolactone44

100 mg per day

Luteal phase

Aldosterone antagonist

Potassium-sparing diuretic

Could improve physical and psychologic symptoms

Dopamine agonist

Bromocriptine4,20,45

Up to 2.5 mg three times per day

Days 10 through 26 of menstrual cycle

May relieve cyclic mastalgia; evaluate hepatic and renal functions before initiation

NSAIDs

Ibuprofen20

500 to 1,000 mg per day

Days 17 through 28 of menstrual cycle

Take with food May relieve mastalgia


PMDD = premenstrual dysphoric disorder; NSAIDs = nonsteroidal anti-inflammatory drugs.

Information from references 4, 20, 44, and 45.

TABLE 6   Miscellaneous Pharmacologic Interventions for PMDD

View Table

TABLE 6

Miscellaneous Pharmacologic Interventions for PMDD

Agents Dosage Use recommendation Comments

Diuretics

Spironolactone44

100 mg per day

Luteal phase

Aldosterone antagonist

Potassium-sparing diuretic

Could improve physical and psychologic symptoms

Dopamine agonist

Bromocriptine4,20,45

Up to 2.5 mg three times per day

Days 10 through 26 of menstrual cycle

May relieve cyclic mastalgia; evaluate hepatic and renal functions before initiation

NSAIDs

Ibuprofen20

500 to 1,000 mg per day

Days 17 through 28 of menstrual cycle

Take with food May relieve mastalgia


PMDD = premenstrual dysphoric disorder; NSAIDs = nonsteroidal anti-inflammatory drugs.

Information from references 4, 20, 44, and 45.

Other Medical Interventions

Historically, surgical and radiation oophorectomies have been used to treat severe PMS, but these modalities have no role in the current management of PMDD.

Evidenced-based efficacy ratings of currently available treatments for PMS and PMDD are described in Table 7,816,1925,2839,4145 while an algorithm for the management of these conditions is outlined in Figure 1.

TABLE 7

Efficacy Rating of Current Treatments for PMS/PMDD

Recommended treatment Efficacy in PMS/PMDD Efficacy rating* Comments/evidence

Lifestyle changes19,20

PMS or PMDD

G

Health benefits without risks

Vitamin B616

PMS or PMDD

B

Dosage > 100 mg per day may cause peripheral neuropathy

Vitamin E20

PMS or PMDD

E

Antioxidant without significant risk

Calcium carbonate21,22

PMS or PMDD

B

Placebo-controlled study supports benefits in moderate to severe PMS

Tryptophan15

PMS or PMDD

B

Supported by a placebo-controlled study

Cognitive-behavioral therapy23

PMS

A

Benefits documented; not many studies

PMDD

B

Herbal therapies24,25

PMS or PMDD

E

Safety in pregnancy and lactation not documented; not FDA-approved

Selective serotonin reuptake inhibitors810,1214,2933,35

Nonresponsive PMS or PMDD

A

Well-designed, randomized, placebo-controlled studies and metaanalyses

Clomipramine11,34

PMDD

B

Anticholinergic side effects

Alprazolam28,3637

PMDD

B

Low-dose, luteal phase treatment; long-term use may cause tolerance

GnRH agonists or danazol18,38,39,41,42

PMDD

C

Menopausal syndrome/masculinization/cost limit its use

Spironolactone, bromocriptine, or ibuprofen41,44,45

PMS or PMDD

D

Symptom-focused efficacy; spironolactone efficacy supported by double-blind study

Oral contraceptives or progesterone42,43

PMDD

E

Anecdotal efficacy or not consistently effective

Surgical or radiation oophorectomy

PMDD

F

Not recommended


PMS = premenstrual syndrome; PMDD = premenstrual dysphoric disorder; FDA = U.S. Food and Drug Administration; GnRH = gonadotropin-releasing hormone.

*—Efficacy rating key: A = first line; B = second line; C = third line; D = symptomatic efficacy; E = efficacy anecdotal or not consistently effective; F = not recommended; G = general or adjunctive treatments.

Information from references 8 through 16, 19 through 25, 28 through 39, an d41 through 45.

TABLE 7   Efficacy Rating of Current Treatments for PMS/PMDD

View Table

TABLE 7

Efficacy Rating of Current Treatments for PMS/PMDD

Recommended treatment Efficacy in PMS/PMDD Efficacy rating* Comments/evidence

Lifestyle changes19,20

PMS or PMDD

G

Health benefits without risks

Vitamin B616

PMS or PMDD

B

Dosage > 100 mg per day may cause peripheral neuropathy

Vitamin E20

PMS or PMDD

E

Antioxidant without significant risk

Calcium carbonate21,22

PMS or PMDD

B

Placebo-controlled study supports benefits in moderate to severe PMS

Tryptophan15

PMS or PMDD

B

Supported by a placebo-controlled study

Cognitive-behavioral therapy23

PMS

A

Benefits documented; not many studies

PMDD

B

Herbal therapies24,25

PMS or PMDD

E

Safety in pregnancy and lactation not documented; not FDA-approved

Selective serotonin reuptake inhibitors810,1214,2933,35

Nonresponsive PMS or PMDD

A

Well-designed, randomized, placebo-controlled studies and metaanalyses

Clomipramine11,34

PMDD

B

Anticholinergic side effects

Alprazolam28,3637

PMDD

B

Low-dose, luteal phase treatment; long-term use may cause tolerance

GnRH agonists or danazol18,38,39,41,42

PMDD

C

Menopausal syndrome/masculinization/cost limit its use

Spironolactone, bromocriptine, or ibuprofen41,44,45

PMS or PMDD

D

Symptom-focused efficacy; spironolactone efficacy supported by double-blind study

Oral contraceptives or progesterone42,43

PMDD

E

Anecdotal efficacy or not consistently effective

Surgical or radiation oophorectomy

PMDD

F

Not recommended


PMS = premenstrual syndrome; PMDD = premenstrual dysphoric disorder; FDA = U.S. Food and Drug Administration; GnRH = gonadotropin-releasing hormone.

*—Efficacy rating key: A = first line; B = second line; C = third line; D = symptomatic efficacy; E = efficacy anecdotal or not consistently effective; F = not recommended; G = general or adjunctive treatments.

Information from references 8 through 16, 19 through 25, 28 through 39, an d41 through 45.

Management of PMS/PMDD

FIGURE 1.

Algorithm for the management of PMS/PMDD. (PMS = premenstrual syndrome; PMDD = premenstrual dysphoric disorder; SSRI = selective serotonin reuptake inhibitor; GnRH = gonadotropin-releasing hormone.)

View Large

Management of PMS/PMDD


FIGURE 1.

Algorithm for the management of PMS/PMDD. (PMS = premenstrual syndrome; PMDD = premenstrual dysphoric disorder; SSRI = selective serotonin reuptake inhibitor; GnRH = gonadotropin-releasing hormone.)

Management of PMS/PMDD


FIGURE 1.

Algorithm for the management of PMS/PMDD. (PMS = premenstrual syndrome; PMDD = premenstrual dysphoric disorder; SSRI = selective serotonin reuptake inhibitor; GnRH = gonadotropin-releasing hormone.)

The Authors

SUBHASH C. BHATIA, M.D., is chief of the Mental Health and Behavioral Science Department at the Department of Veterans Affairs, Nebraska–Western Iowa Health Care System, Omaha. He is also professor of psychiatry at Creighton University School of Medicine and clinical associate professor at the University of Nebraska College of Medicine, both in Omaha. A medical graduate of Panjab University, Chandigarh, India, Dr. Bhatia received a graduate degree from the Postgraduate Institute of Medical Education and Research, also in Chandigarh, and completed a residency in psychiatry at Creighton University. Dr. Bhatia is board-certified in psychiatry, geriatric psychiatry, addiction psychiatry, and forensic psychiatry.

SHASHI K. BHATIA, M.D., is director of child and adolescent residency education and training at Creighton University School of Medicine, where she is also associate professor of psychiatry, child and adolescent psychiatry, and pediatrics. In addition, she serves as clinical associate professor at the University of Nebraska College of Medicine. A medical graduate of Panjab University, Dr. Bhatia completed a residency in obstetrics and gynecology at the Postgraduate Institute of Medical Education and Research and a residency in psychiatry and child psychiatry at Creighton University. Dr. Bhatia is board-certified in psychiatry, child and adolescent psychiatry, addiction psychiatry, and forensic psychiatry.

Address correspondence to Subhash C. Bhatia, M.D., Chief, Mental Health and Behavioral Science Department, Department of Veterans Affairs, Nebraska–Western Iowa Health Care System, 4101 Woolworth Ave., Omaha, NE 68105 (e-mail: subhash.bhatia@med.va.gov). Reprints are not available from the authors.

The authors thank Daniel Richard Wilson, M.D., Ph.D., Professor and Chair, Creighton University School of Medicine, Department of Psychiatry, for constructive suggestions for the manuscript.

Dr. Shashi Bhatia is a member of the speakers bureaus of Abbot Laboratories and Forest Pharmaceutical, Inc. Dr. Subhash Bhatia is a member of the speakers bureaus for Eli Lilly and Co., Pfizer US Pharmaceutical Group, and Forest Pharmaceutical, Inc. Sources of funding: none reported.

REFERENCES

1. Premenstrual syndrome. ACOG committee opinion. No. 155-April 1995 (replaces no. 66, January 1989). Int J Gynaecol Obstet. 1995;50:80–4.

2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:715–8.

3. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res. 1996;65:97–106.

4. Parry BL, Rausch JL. Premenstrual dysphoric disorder. In: Kaplan HI, Sadock BJ, Cancro R, eds. Comprehensive textbook of psychiatry. 6th ed. Baltimore: Williams & Wilkins, 1995:1707–13.

5. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry. 1997;58(suppl 15):19–25.

6. Endicott J, Amsterdam J, Eriksson E, Frank E, Freeman E, Hirschfeld R, et al. Is premenstrual dysphoric disorder a distinct clinical entity?. J Womens Health Gend Based Med. 1999;8:663–79.

7. Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry. 1998;155:1234–40.

8. Freeman EW, Rickels K, Arredondo F, Kao LC, Pollack SE, Sondheimer SJ. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol. 1999;19:3–8.

9. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry. 1997;58:399–402.

10. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Arch Fam Med. 1999;8:328–32.

11. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome. Neuropsychopharmacology. 1993;9:133–45.

12. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull. 1997;33:771–4.

13. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, et al. Citalopram in premenstrual dysphoria. J Clin Psychopharmacol. 1998;18:390–8.

14. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase. J Clin Psychiatry. 1998;59:76–80.

15. Steinberg S, Annable L, Young SN, Liyanage N. A placebo-controlled clinical trial of l-tryptophan in pre-menstrual dysphoria. Biol Psychiatry. 1999;45:313–20.

16. Wyatt KM, Dimmock PW, Jones PW, Shaughn O’Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome. BMJ. 1999;318:1375–81.

17. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull. 1997;33:303–9.

18. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209–16.

19. Johnson WG, Carr-Nangle RE, Bergeron KC. Macronutrient intake, eating habits, and exercise as moderators of menstrual distress in healthy women. Psychosom Med. 1995;57:324–30.

20. Bowman MA. Premenstrual syndrome. In: Dambro MR, Griffith JA, eds. Griffith’s 5 minute clinical consult, 2000. Philadelphia: Lippincott Williams & Wilkins, 2000:862–3.

21. Ward MW, Holimon TD. Calcium treatment for pre-menstrual syndrome. Ann Pharmacother. 1999;33:1356–8.

22. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol. 1998;179:444–52.

23. Christensen AP, Oei TP. The efficacy of cognitive behaviour therapy in treating premenstrual dysphoric changes. J Affect Disord. 1995;33:57–63.

24. Hardy ML. Herbs of special interest to women. JAm Pharm Assoc (Wash). 2000;40:234–42.

25. Blumenthal M, Gruenwald J, Hall T, Riggins C, Rister R. In: Blumenthal M, Busse WR, eds. The complete German Commission E monographs, therapeutic guide to herbal medicines. Austin, Tex.: American Botanical Council, 1998.

26. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322:134–7.

27. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, et al. Fluoxetine in the treatment of pre-menstrual dysphoria. N Engl J Med. 1995;332:1529–34.

28. Diegoli MS, da Fonseca AM, Diegoli CA, Pinotti JA. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet. 1998;62:63–7.

29. Romano S, Judge R, Dillon J, Shuler C, Sundell K. The role of fluoxetine in the treatment of premenstrual dysphoric disorder. Clin Ther. 1999;21:615–33.

30. Eriksson E, Hedberg MA, Andersch B, Sunblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 1995;12:167–76.

31. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder. Arch Gen Psychiatry. 1999;56:932–9.

32. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA. 1997;278:983–8.

33. Cohen LS. Sertraline for premenstrual dysphoric disorder. JAMA. 1998;279:357–8.

34. Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria. Acta Psychiatr Scand. 1992;85:39–47.

35. Dimmock PW, Wyatt KM, Jones PW, O’Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome. Lancet. 2000;356:1131–6.

36. Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder. Obstet Gynecol. 1994;84:379–85.

37. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe pre-menstrual syndrome. JAMA. 1995;274:51–7.

38. Hammarbäck S, Bäckstrom T. Induced anovulation as treatment of premenstrual tension syndrome. Acta Obstet Gynecol Scand. 1988;67:159–66.

39. Leather AT, Studd JW, Watson NR, Holland EF. The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy. Gynecol Endocrinol. 1999;13:48–55.

40. Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome. Obstet Gynecol. 1994;84:779–86.

41. Hahn PM, Van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology. 1995;20:193–209.

42. Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Br J Gen Pract. 1995;45:589–93.

43. Vanselow W, Dennerstein L, Greenwood KM, de Lignieres B. Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol. 1996;17:29–38.

44. Wang M, Hammarbäck S, Lindhe BA, Bäckstrom T. Treatment of premenstrual syndrome by spironolactone. Acta Obstet Gynecol Scand. 1995;74:803–8.

45. Meden-Vrtovec H, Vujic D. Bromocriptine (Bromergon, Lek) in the management of premenstrual syndrome. Clin Exp Obstet Gynecol. 1992;19:242–8.


Copyright © 2002 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article